Watch More Highlights
Gloria Espinosa, PharmD, MAT, BCOP, of Thomas Jefferson University Hospital, discusses efficacy and safety data for the first-in-class menin inhibitor, revumenib, in patients with relapsed/refractory KMT2A-rearranged acute leukemia. The results show clinically meaningful outcomes and the most common treatment-related adverse events to be nausea, differentiation syndrome, and QTc prolongation (LBA-5).